Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TEPOTINIB HYDROCHLORIDE
- Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
- POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
- A Phase 1b/2 Study of Tepotinib in Combination With Paclitaxel in Patients With MET Amplified or MET Exon 14 Alterated Advanced Gastric and Gastroesophageal Junction Carcinoma
- Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
- Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants
- A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
- Tepotinib in Solid Tumors Harboring MET Alterations
- Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
- Bioequivalence of 5 Tablets of 100 Milligrams (mg) Versus 2 Tablets of 250 mg Tablet Formulation 3 (TF3) of Tepotinib
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
- Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of Tepotinib
- Effect of Tepotinib on Pharmacokinetics (PK) of Cytochrome P450 (CYP) 3A Substrate Midazolam
- Tepotinib Hepatic Impairment Trial
- Effect of a Proton Pump Inhibitor on the Pharmacokinetics (PK) of Tepotinib
- Effect of Tepotinib on the Pharmacokinetics (PK) of the P-glycoprotein (P-gp) Substrate Dabigatran Etexilate
- Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
- c-Met Second-Line Hepatocellular Carcinoma
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
- First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Clinical trials list
click for details